Statistical models to predict clinical outcomes with anakinra vs. tocilizumab treatments for severe pneumonia in COVID19 patients

Comparing Worldwide, National, and Independent Notifications about Adverse Drug Reactions Due to COVID-19 Vaccines

The rapid development of effective vaccines against COVID-19 is an extraordinary achievement. However, no medical product can ever be considered risk-free. Several countries have a pharmacovigilance system that detects, assesses, understands, and …

Predicting the spread of the SARS-CoV-2 in Italian regions: the Calabria case study, February 2020 - March 2022

Despite the stunning speed with which highly effective and safe vaccines have been developed, the emergence of new variants of SARS‑CoV‑2 causes high rates of (re)infection, a major impact on health care services, and a slowdown to the socio-economic …

Impact of the additional/booster dose of COVID-19 vaccine against severe disease during the epidemic phase characterized by the predominance of the Omicron variant in Italy, December 2021 - May 2022

Vaccine effectiveness (VE) against emerging SARS-CoV-2 variants is a growing issue. The aim of this work is to evaluate the impact of the COVID-19 additional/booster dose against COVID-19-related symptoms, hospitalization, and death using …

Contagi e vaccini a portata di click

Operativa la piattaforma Covida, ideata e realizzata all'Unical